Dopamine Hypothesis is linked with Neural Stem Cell (NSC) Dysfunction Hypothesis by D-Cell Hypothesis (Trace Amine Hypothesis) in Etiology of Schizophrenia

Keiko Ikemoto*

1 Department of Psychiatry, Iwaki Kyoritsu General Hospital, Iwaki 973-8555, Japan

Abstract

Mesolimbic dopamine (DA) hyperactivity is a well-known pathophysiological hypothesis of schizophrenia. The author intended to show a new hypothesis to clarify the molecular basis of mesolimbic DA hyperactivity of schizophrenia. The Dopamine Hypothesis is linked with Neural Stem Cell (NSC) Dysfunction Hypothesis by D-Cell Hypothesis (Trace Amine Hypothesis) in Etiology of Schizophrenia. The highlight is the rational that the “D-cell hypothesis (TA hypothesis) of schizophrenia” is a pivotal theory to link NSC dysfunction hypothesis to DA hypothesis. From a therapeutic direction, (1) TAAR1 agonists, (2) DA D2 antagonists, and (3) neurotranscopic substances have potential to normalize mesolimbic DA hyperactivity. To further develop novel therapeutic strategies, metabolisms of TAAR1 ligands, and NSC- and D-neuron-pathophysiology of neuropsychiatric illnesses remain to be explored.

Keywords: Dopamine; D-cell; Trace amine; Schizophrenia; TAAR1; Neural stem cell

Introduction

Dopamine (DA) dysfunction [1,2], glutamate dysfunction [3,4], neurodevelopmental deficits [5,6], or neural stem cell (NSC) dysfunction [7,8] are well-known hypotheses for etiology of schizophrenia. DA dysfunction hypothesis suggested that mesolimbic DA hyperactivity caused positive symptoms such as paranoid-hallucinatory state of schizophrenia [1,2]. It is also explained by the efficacy of DA D2 blockers for paranoid-hallucinatory state and also by hallucinogenic acts of DA stimulants including methamphetamine or amphetamine [1,2]. Glutamate dysfunction theory was induced by the fact that intake of phencyclidine (PCP), an antagonist of N-methyl-D-aspartate (NMDA) receptor, produces equivalent to negative symptoms of schizophrenia, such as withdrawal or flattened affect, as well as positive symptoms [3,4]. The neurodevelopmental deficits hypothesis implicates that schizophrenia is the consequence of prenatal abnormalities resulting from the interaction of genetic and environmental factors [5,6]. NSC dysfunction has also been shown to be a cause of schizophrenia [7,8]. Although mesolimbic DA hyperactivity [1,2] has been well documented in pathogenesis of schizophrenia, the molecular basis of this mechanism has not yet been detailed. In the present article, the author showed the rational of the reduction of putative trace amine (TA)-producing neurons (D-neurons), that is, ligand neurons of TA-associated receptor, type 1 (TAAR1), in the striatum in the pathogenesis of mesolimbic DA hyperactivity of schizophrenia [9]. The novel hypothesis, “D-cell hypothesis of schizophrenia”, is a critical theory to link NSC dysfunction hypothesis with DA hypothesis in etiology of schizophrenia.

D-neuron

The “D-cell” was described, by Jaeger et al. [10], in 1983 in the rat central nervous system and was defined “the non-monaminergic aromatic L-amino acid decarboxylase (AADC)-containing cell”. AADC contains AADC but not dopaminergic nor serotonergic [10]. Then, it is natural that the D-cell is thought to produce TAs [11,12], such as β-phenylethylamine (PEA), tyramine, tryptamine and octopamine. AADC is the rate-limiting enzyme for TA synthesis. However, it is confusing that these TAs are also “monoamines”, as each one has one amino residue. It would be better to use the nomenclature of “TA neurons” for D-cells, and “TA neurons” for D-neurons. In the present article, the author uses the words, D-cell and D-neuron, signifying TA cell and TA neuron, respectively. The localizations of D-cells were specified into 14 groups, from D1 (the spinal cord) to D14 (the bed nucleus of stria terminalis) in caudo-rostral orders of the rat central nervous system using AADC immunohistochemistry [13]. In this usage, the classification term “D” means decarboxylation. In rodents [14,15], a small number of D-cells in the striatum were rostrally described and confirmed to be neurons by electron-microscopic observation [14,15]. I reported in 1997, “dopa-decarboxylating neurons specific to the human striatum [16-19]”, that is, “D-neurons” in the human striatum [18,20] (classified to be D15) [18], though monkey striatum did not contain D-neurons [18]. In 2003, by using pathological and legal autopsy brains of patients with schizophrenia, reduction of D-neurons in the striatum, including nucleus accumbens (Acc) (classified to be D16) of patients with schizophrenia [9,20] was also shown.

*Corresponding author: Keiko Ikemoto, Department of Psychiatry, Iwaki Kyoritsu General Hospital, Iwaki 973-8555, Japan, E-mail: ikemoto@iwaki-kyoritsu.iwaki.fukushima.jp

Received December 16, 2014; Accepted March 04, 2015; Published March 11, 2015

Citation: Ikemoto K (2015) Dopamine Hypothesis is linked with Neural Stem Cell (NSC) Dysfunction Hypothesis by D-Cell Hypothesis (Trace Amine Hypothesis) in Etiology of Schizophrenia. Biochem Physiol 4: 152. doi: 10.4172/2168-9652.1000152

Copyright: © 2015 Ikemoto K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Trace Amine (TA)-Associated Receptor, Type 1 (TAAR1)

Cloning of TA receptors in 2001 [21,22], elicited enormous efforts for exploring signal transduction of these G-protein coupled receptors whose genes are located on chromosome focus 6q23.1 [23]. The receptors have been shown to co-localize with DA or adrenaline transporters in monoamine neurons and to modulate the functions of monoamines [24–26]. The TAAR1 having a large number of ligands, including, PEA, tyramine, 3-iodothyronamine, 3-methoxytyramine, normetanephrine, and psychostimulants, for example methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA) and lysergic acid diethylamide (LSD) [21,23,26], has become a target receptor for exploring novel neuroleptics [27,28]. However, endogenous TAAR1 ligands in the human central nervous system have not yet been specified. TAAR1 knockout mice showed schizophrenia-like behaviors with a deficit in prepulse inhibition [29,30]. TAAR1 knockout mice showed greater locomotor response to amphetamine and released more DA (and noradrenaline) in response to amphetamine than wild type mice [29]. It has been shown that TAAR1 has a thermoregulatory function [30]. As is the important fact, it was clarified that increased stimulation of TAAR1 receptors on cell membranes of DA neurons in the midbrain ventral tegmental area (VTA) reduced firing frequency of VTA DA neurons [27–30]. This made the author to suspect the existence of critical role of TAAR1 stimulation decrease for mesolimbic DA hyperactivity in schizophrenia.

A New “D-Cell Hypothesis” of Schizophrenia

A new theory, “D-cell hypothesis”, to explain mesolimbic DA hyperactivity in pathogenesis of schizophrenia is shown in Figure 1. In brains of patients with schizophrenia, dysfunction of NSC in the subventricular zone of lateral ventricle causes D-neuron decrease in the striatum and Acc [8,31]. This induces TA decrease in these nuclei, though direct evidences have not yet been demonstrated. Enlargement of the lateral ventricle [32,33], a usual finding documented in brain imaging studies of schizophrenia, is probably due to NSC dysfunction in the subventricular zone [7,8]. The reduction of TAAR1 stimulation on DA terminals of VTA DA neurons, caused by TA decrease, would increase firing frequency of VTA DA neurons [28,30,31]. This increases DA release and DA turnover in the Acc [2], resulting in mesolimbic DA hyperactivity. It has been shown that D2 stimulation of NSC in the striatum inhibited forebrain NSC proliferation [31,34]. Striatal DA hyperactivity may accelerate D-neuron decrease, which accelerates hyperactivity of mesolimbic DA system [35]. Actions of D2 blocking agents in pharmacotherapy of schizophrenia might be explained by blocking the inhibition to forebrain NSC proliferations, and also by formation of TAAR1 ligands, such as 3-methoxytyramine and

![Figure 1: Scheme of D-cell hypothesis (trace amine (TA) hypothesis) of schizophrenia](image-url)

In schizophrenia brain, dysfunction of neural stem cells (NSC) in the subventricular zone (SVZ) of lateral ventricle causes D-neuron decrease in the striatum and nucleus accumbens (Acc) [8,31]. This induces TA decrease in these nuclei and TAAR1 stimulation decrease onto DA terminals of VTA DA neurons, causing firing frequency increase in VTA DA neurons [28,30,31]. This increases DA release and DA turnover in the Acc, being the molecular basis of mesolimbic DA hyperactivity. Striatal DA hyperactivity causes excessive D2 stimulation of NSC in the striatum and inhibits forebrain NSC proliferation [31,34], which accelerates D-neuron decrease and accelerates mesolimbic DA hyperactivity.

To inhibit this cycle of pathological progression, ①–③ intervention is effective.

① TAAR1 agonists
② D2 antagonists
③ Neurotrophic substances
1. Early intervention for first episode schizophrenia by D2 blockers inhibits this cycle [35]
2. Chronic D2 blocker administration has preventive effect for recurrence of psychoses
3. D2 blockers increase TAAR1 ligands [36]

Brain-derived neurotrophic factor (BDNF), lithium, anticonvulsants, antidepressants, having neurotrophic effects, activate NSC functions [36].
normetanephrine [36]. It is consistent with clinical evidences that initial pharmacotherapy using D2 antagonists is proved to be critical for preventing progressive pathognomonic procedures of schizophrenia [35].

Disease Progression of Schizophrenia and Therapeutic Strategies

D-cell hypothesis not only links DA hypothesis with NSC dysfunction hypothesis, but also explains the mechanisms of disease progression of schizophrenia as shown in Figure 1. To inhibit this cycle of pathological progression, intervention indicated by ①~③, shown in Figure 1, is supposed to be effective.

1) TAAR1 agonists (Figure 1 ①)

Early studies have shown formation of some TAAR1 ligands by administration of D2 antagonists including haloperidol and chlorpromazine [35]. In recent animal studies, effectiveness of TAAR1 ligands for schizophrenia-like symptoms of schizophrenia model animals has been shown [28].

2) D2 antagonists (Figure 1 ②)

Duration of untreated psychosis is a predictor of long-term outcome of schizophrenia [35]. Importance of early intervention for first episode schizophrenia by using D2 antagonist has been emphasized. Chronic D2 blocker administration has preventive effect for recurrence of psychoses. D2 antagonists may block disease progression as shown in Figure 1 ②. D2 antagonists have dual actions for inhibiting this cycle of disease progression by also forming some TAAR1 ligands (3-methoxytyramine, normetanephrine) which may increase TAAR1 stimulation as shown in Figure 1 ① [35].

3) Neurotrophic substances (Figure 1 ③)

Disease progression would be inhibited by neurotrophic substances (Figure ③), for example, brain-derived neurotrophic factor (BDNF), lithium, anticonvulsants, or antidepressants. These substances, having neurotrophic effects, activate NSC functions [37], and inhibit striato-accumbal D-neuron decrease.

4) Intranasal administration of drugs, expecting retrograde transport of neuroactive substances or their precursors through the olfactory bulb, might be a novel therapeutic strategy (①~③). It is a possible preferable method of administration, as it avoid of gastrointestinal side effects [38-40]. In this context, further investigation remain to be performed.

Some Evidence Supporting D-Cell Hypothesis of Schizophrenia (Table 1)

Although it has not yet been detailed which type of TA in the human central nervous system is related to psychiatric symptoms, nor has been identified the endogenous ligands of human TAAR1, clinical and/or pharmacological observations may enable us to determine the critical type of TA. Further, the type of TA that is synthesized in human striatal D-neurons has not yet been clarified. Early in 1974, Sabelli and Mosnaim [41] proposed “Phenylethylamine hypothesis of affective behavior”, indicating the involvement of TA in animal behaviors. PEA, having the similar chemical structure of methamphetamine, is the most probable TA which effects on psychiatric symptoms. One of the initial clinical symptoms frequently observed in first episode schizophrenia is the disturbance of sleep-wake-rhythm, that is, insomnia and daytime hypersomnia. As PEA is the specific substrate for monoamine oxidase, type B (MAOB), MAOB knockout mice contained elevated level of PEA in the striatum by 8-10 times of that of controls [42]. Clinically, MAOB inhibitor, selegiline ameliorates daytime sleepiness of narcolepsy or other neuropsychiatric diseases (By PEA increase?). Decreased level of plasma brain-derived neurotrophic factor (BDNF) in patients with schizophrenia [37]

Table 1: Possible evidence supporting “D-cell hypothesis” (“Trace amine (TA) hypothesis”).

| Trace amine (TA) |
|------------------|
| 1 Disturbance of sleep-wake-rhythm of patients with schizophrenia (insomnia and daytime hypersomnia) |
| 2 Phenylethylamine hypothesis of affective behavior [41] |
| 3 Decrease of TA neurons (=D-neurons) in post-mortem brains of schizophrenics [9] |
| 4 Chocolate (which include β-phenylethylamine (PEA) habit of Novel Prizewinners [44]) |
| 5 Excessive chocolate intake of children be generally restricted (Possible prevention of D-neuron down regulation) |
| 6 D2 blockers form ligands of TA-associated receptor, type 1 (TAAR1) acting as also antipsychotics [36] |

| Monoamine oxidase, type B (MAOB) and β-phenylethylamine (PEA) |
|---------------------------------------------------------------|
| PEA be specific substrate for MAOB (tyramine for both monoamine oxidase, type A (MAOA) and MAOB) |
| 1 MAOB knockout mice contained elevated level of PEA in the striatum by 8-10 times of that of controls [42] |
| 2 Clinically, MAOB inhibitor, selegiline ameliorates daytime sleepiness of narcolepsy or other neuropsychiatric diseases (By PEA increase?) |
| 3 In schizophrenia, insomnia and daytime sleepiness be frequently observed as initial symptoms (By PEA decrease) |
| 4 Increased DNA methylation rate of MAOB gene in the nucleus accumbens (Acc) of postmortem brains of schizophrenia (Compensation for PEA decrease due to lack of D-neurons) [43] |

| Neural stem cell (NSC) |
|-----------------------|
| 1 NSC dysfunction hypothesis of schizophrenia |
| 2 Ventricular enlargement in brain imaging of patients with schizophrenia [32,33] |
| 3 Decrease of D-neurons in Acc of patients with schizophrenia [9] |
| 4 Decreased level of plasma brain-derived neurotrophic factor (BDNF) in patients with schizophrenia [37] |
This indicates that the molecular basis of efficacy of D2 antagonists may be effects also via TAAR1 stimulation by 3-methoxytyramine and/or normetanephrine. Ventricular enlargement in brain imaging of patients with schizophrenia [32,33] may be the similar phenomenon to D-neuron decrease in the striatum of schizophrenia [9], both of which support NSC dysfunction hypothesis of schizophrenia. Decreased level of plasma brain-derived neurotrophic factor (BDNF) in schizophrenia [40] is also related to NSC dysfunction. Some evidence supporting D-cell hypothesis of schizophrenia is summarized in Table 1.

Prognoses of Neuropsychiatric Illnesses

"D-cell hypothesis", which is proposed by a postmortem brain study of schizophrenia, explains molecular mechanism of mesolimbic DA hyperactivity of schizophrenia, linking NSC dysfunction hypothesis with DA hypothesis. Such D-cell-involved etiological dynamism in schizophrenia may exist in wide spectrum of mental illnesses, and also in neurological illnesses [45]. As shown in Figure 1, NSC functions affect not only on D-neuron activity, but also clinical course and prognoses of neuropsychiatric illnesses.

Conclusion

The D-neuron, i.e., the TA neuron, is a clue for pathogenesis of neuropsychiatric illnesses. Exploration of endogenous TAAR1 ligands, and NSC- and D-neuron-mediated signal transduction of normal and/or disease state(s) is critical for future direction of neuropsychiatric research.

Acknowledgement

The present study was supported by Grant-in-Aid for Scientific Research from Japan Society for the Promotion of Science (C-22591265, "How are trace amines involved in pathophysiology of schizophrenia?").

References

1. Hökfelt T, Ljungdahl A, Fuxe K, Johansson O (1974) Dopamine nerve terminals in the rat limbic system: c-fos aspects of the dopamine hypothesis of schizophrenia. Science 184: 177-179.
2. Toru M, Nishikawa T, Mataga N, Takashima M (1982) Dopamine metabolism increases in post-mortem schizophrenic basal ganglia. J Neural Transm 54: 181-191.
3. Watia L, Chen SH, Chua HC, Chong SA, Sim K (2008) Glutamatergic abnormalities of the thalamus in schizophrenia: a systematic review. J Neural Transm 115: 493-511.
4. Olbrich HM, Valerius G, Rüsch N, Buchert M, Thiel T, et al. (2008) Frontolimbic glutamate alterations in first episode schizophrenia: evidence from a magnetic resonance spectroscopy study. World J Biol Psychiatry 9: 59-63.
5. Christidou GW, Casanova MF, Weinberger DR, Rawlings R, Kleinman JE (1989) A quantitative investigation of hippocampal pyramidal cell size, shape, and variability of orientation in schizophrenia. Arch Gen Psychiatry 46: 1027-1032.
6. McGlashan TH, Hoffman RE (2000) Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch Gen Psychiatry 57: 637-648.
7. Duan X, Chang JH, Ge S, Faulkner RL, Kim JY, et al. (2007) Diurupted-In-Schizophrenia 1 regulates integration of newly generated neurons in the adult brain. Cell 130: 1146-1158.
8. Reif A,Fritzen S, Finger M, Strobel A, Lauer M, et al. (2006) Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Mol Psychiatry 11: 514-522.
9. Ikemoto K, Nishimura A, Oda T, Nagatsu I, Nishi K (2003) Number of striatal D-neurons is reduced in autopsy brains of schizophrenics. Leg Med (Tokyo) 5 Suppl 1: S221-224.
10. Jaeger CB, Teitelman G, Joh TH, Albert VR, Park DH, et al. (1983) Some neurons of the rat central nervous system contain aromatic-L-amino-acid decarboxylase but not monoamines. Science 219: 1233-1235.
11. Boulton AA (1974) Letter: Amines and theories in psychiatry. Lancet 2: 52-53.
12. Boulton AA, Jurio AV (1979) Thyramines: are they involved in the psychoses? Biol Psychiatry 14: 413-419.
13. Jaeger CB, Ruggiero DA, Albert VR, Park DH, Joh TH, et al. (1984) Aromatic L-amino acid decarboxylase in the rat brain: immunocytochemical localization in neurons of the brain stem. Neuroscience 11: 691-713.
14. Tashiro Y, Kaneko T, Sugimoto T, Nagatsu I, Kikuchi H, et al. (1989) Striatal neurons with aromatic L-amino acid decarboxylase-like immunoreactivity in the rat. Neurosci Lett 100: 29-34.
15. Mura A, Linder JC, Young SJ, Groves PM (2000) Striatal cells containing aromatic L-amino acid decarboxylase: an immunohistochemical comparison with other classes of striatal neurons. Neuroscience 98: 501-511.
16. Ikemoto K,Kitahama K, Jouvet A, Ariai R, Nishimura A, et al. (1997) Demonstration of L-dopa decarboxylating neurons specific to human striatum. Neurosci Lett 232: 111-114.
17. Ikemoto K, Nagatsu I, Kitahama K, Jouvet A, Nishimura A, et al. (1998) A dopamine-synthesizing cell group demonstrated in the human basal forebrain by dual labeling immunohistochemical technique of tyrosine hydroxylase and aromatic L-amino acid decarboxylase. Neurosci Lett 243: 129-132.
18. Kitahama K,Ikemoto K, Jouvet A, Nagatsu I, Sakamoto N, et al. (1998)Aromatic L-amino acid decarboxylase- and tyrosine hydroxylase-immunohistochemistry in the adult human hypothalamus. J ChemNeuroanat 16: 43-55.
19. Kitahama K,Ikemoto K, Jouvet A, Araneda S, Nagatsu I, et al. (2009) Aromatic L-amino acid decarboxylase-immunoreactive structures in human midbrain, pons, and medulla. J ChemNeuroanat 38: 130-140.
20. Ikemoto K (2004) Significance of human striatal D-neurons: implications in neuropsychiatric functions. ProgNeuropsychopharmacol Biol Psychiatry 28: 429-434.
21. Burzov JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, et al. (2001) Amphetamine, 34-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol 60: 1181-1188.
22. Borowsky B,Adham N, Jones KA, Raddatz R, Artyushyn R, et al. (2001) Trace amines: identification of a family of mammalian G protein-coupled receptors. ProcNatAcadSci U S A 98: 8966-8971.
23. Miller GM (2011) The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. J Neurochem 116: 164-176.
24. Xie Z, Miller GM (2009) Trace amine-associated receptor 1 as a monoaminergic modulator in brain. Biochem Pharmacol 78: 1095-1104.
25. Lindemann M, Meyer CA, Jeanneau K, Bradaia A, Ozmen L, et al. (2008) Trace amine-associated receptor 1 modulates dopaminergic activity. J Pharmacol ExpTher 324: 948-956.
26. Zucchi R,Chellini G, Scanlan TS, Grandy DK (2006) Trace amine-associated receptors and their ligands. Br J Pharmacol 149: 967-978.
27. Bradaia A,Truge B, Stalder H, Norcross RD, Ozmen L, et al. (2009) The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimic system. ProcNatAcadSci U S A 106: 20001-20008.
28. Revel FG, Moreau JL, Pouzet B, Mory R, Bradaia A, et al. (2013) A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight. Mol Psychiatry 18: 543-556.
29. Panas NH, Lynch L, Vallender EJ, Xie Z, Chen GL, et al. (2010) Normal thermoregulatory responses to 3-iodothyronamine, trace amines and amphetamine-like psychostimulants in trace amine associated receptor 1 knockout mice. J Neurosci Res 88: 1962-1969.
30. Wolinsky TD, Swanson CJ, Smith KE, Zhong H, Borowsky B, et al. (2007) The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav 6: 628-639.
31. Sanai N,Tramontin AD, Quiñones-Hinojosa A, Barbaro NM, Gupta N, et al. (2004) Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature 427: 740-744.
32. Degreff G, Ashtari M, Bogerts B, Bilder RM, Jody DN, et al. (1992) Volumes of ventricular system subdivisions measured from magnetic resonance images in first-episode schizophrenic patients. Arch Gen Psychiatry 49: 531-537.

33. Horga G, Bernacch J, Dusi N, Entis J, Chu K, et al. (2011) Correlations between ventricular enlargement and gray and white matter volumes of cortex, thalamus, striatum, and internal capsule in schizophrenia. Eur Arch Psychiatry Clin Neurosci 261: 467-476.

34. Kippin TE, Kapur S, van der Kooy D (2005) Dopamine specifically inhibits forebrain neural stem cell proliferation, suggesting a novel effect of antipsychotic drugs. J Neurosci 25: 5815-5823.

35. Penttilä M, Jääskeläinen E, Hirvonen N, Isohanni M, Miettunen J (2014) Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 205: 88-94.

36. Carlsson A, Lindqvist M (1963) Effect Of Chlorpromazine Or Haloperidol On Formation Of 3methoxytyramine And Normetanephrine In Mouse Brain. Acta Pharmacol Toxicol (Copenh) 20: 140-144.

37. Fernandes BS, Steiner J, Berk M, Molendijk ML, Gonzalez-Pinto A, et al. (2014) Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications. Mol Psychiatry.

38. Piazza J, Hoare T, Molinario L, Terpstra K, Bhandari J, et al. (2014) Haloperidol-loaded intranasally administered lectin functionalized poly(ethylene glycol)-block-poly(D,L)-lactic-co-glycolic acid (PEG-PLGA) nanoparticles for the treatment of schizophrenia. Eur J Pharm Biopharm 87: 30-39.

39. Wen Z, Yan Z, Hu K, Pang Z, Cheng X, et al. (2011) Odorrranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson’s disease following intranasal administration. J Control Release 151: 131-138.

40. Ikemoto K, Nishi K, Nishimura A (2014) Lectin-positive spherical deposit (SPD) in the molecular layer of hippocampal dentate gyrus of dementia, Down’s syndrome, schizophrenia. J Alzheimers Dis Parkinsonism 4: 1000169.

41. Sabeli HC, Mosnaim AD (1974) Phenylethylamine hypothesis of affective behavior. Am J Psychiatry 131: 695-699.

42. Grimsby J, Toth M, Chen K, Kumazawa T, Klaidman L, et al. (1997) Increased stress response and beta-phenylethylamine in MAOB-deficient mice. Nat Genet 17: 206-210.

43. Yang QH, Ikemoto K, Nishino S, Yamaki J, Kuni Y, et al. (2012) DNA methylation of the Monoamine Oxidases A and B genes in postmortem brains of subjects with schizophrenia. J Jpn Psychiatr Soc 2: 374-383.

44. Golomb BA, Brenner S, Chalfie M, Glashow SL, Glauber RJ, et al. (2013) Chocolate habits of Nobel prizewinners. Nature 499: 409.

45. Bachmann RF, Schloesser RJ, Gould TD, Manji HK (2005) Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics. Mol Neurobiol 32: 173-202.